Twist Bioscience Corp
TWST evidence brief
What we can confirm
- BioSniper Score:
- 4.6 / 10
- Market Cap:
- $8.43B
What it means
What to watch
Prepared research question
What matters most for TWST—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TWST
Twist Bioscience Corp (TWST) is a publicly traded synthetic biology company that manufactures synthetic DNA and provides next-generation sequencing (NGS) tools, with growing AI-enabled drug discovery and NGS businesses.
Key risk: Valuation demanding
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$8.43B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials for Twist Bioscience Corp.
Twist Bioscience Corp (TWST) is a publicly traded synthetic biology company that manufactures synthetic DNA and provides next-generation sequencing (NGS) tools, with growing AI-enabled drug discovery and NGS businesses.
- Cash & equivalents of $117.4M as of 2026-06-30 [sec].
- Total revenue of $118.4M as of 2026-06-30 [sec].
- Net income of -$35.1M as of 2026-06-30 [sec].
- Shareholders' equity of $445.7M as of 2026-06-30 [sec].
- AI drug discovery and NGS businesses show growth [news · published 2026-08-03].
What works
- AI drug discovery and NGS businesses show growth [news · published 2026-08-03].
- Stock is up on strong Q3 results and raised guidance [news · published 2026-08-03].
- Improving margins noted in 2026 [news · published 2026-08-05].
What to weigh
- Valuation concerns remain despite growth [news · published 2026-08-05].
- Net loss of -$35.1M as of 2026-06-30 [sec].
- Valuation looks demanding [news · published 2026-08-05].
From the filings
Quoted directly from source documents.
Growth in AI drug discovery and NGS
“AI drug discovery and NGS businesses show growth”
News · August 3, 2026
Catalyst timeline
- 2018-09-06 · Phase2_Start: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer — A Phase II study of autologous T-cells engineered to target neoantigens in metastatic cancer.
- 2024-05-16 · Phase1_Start: A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer — A Phase Ib trial of T-cells engineered against KRAS mutations combined with a vaccine in metastatic cancer.
Risks & what to watch (2)›
Key risks
- Valuation demanding — Valuation looks demanding despite growth [news · published 2026-08-05].
- Net loss persists — Net income of -$35.1M as of 2026-06-30 [sec].
What to watch
- AI drug discovery pipeline expansion [news · published 2026-08-03].
- NGS business growth trajectory [news · published 2026-08-03].
- Margin improvement sustainability [news · published 2026-08-05].
Sources: Catalysts · Competitor trials · News · Generated October 4, 2026 · How we verify sources →
Run Twist Bioscience Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Twist Bioscience Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.51 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 75 sells (180d)
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 28.7%
- Days to cover
- 11.0
- Shares short
- 13,914,949
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TWST short interestGovernance
Frequently asked questions
What is the AI investment thesis for Twist Bioscience Corp?
Twist Bioscience Corp (TWST) is a publicly traded synthetic biology company that manufactures synthetic DNA and provides next-generation sequencing (NGS) tools, with growing AI-enabled drug discovery and NGS businesses.
Who is the CEO of Twist Bioscience Corp?
Dr. Emily Marine Leproust Ph.D. is the chief executive officer of Twist Bioscience Corp (TWST).
Where is Twist Bioscience Corp headquartered?
Twist Bioscience Corp (TWST) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Twist Bioscience Corp focus on?
Twist Bioscience Corp develops therapies across Oncology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.